Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.34 |
| ▸ | CDC25B | P30305 | 7/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | GJB2 | P29033 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20434838 | 0.88 | PDE2A (0.38) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL30592031 | 0.88 | PDE2A (0.38) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL21759078 | 0.88 | PDE2A (0.38) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL24539016 | 0.88 | PDE2A (0.38) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL18490453 | 0.88 | PDE2A (0.38) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL19223088 | 0.85 | PTPN1 (0.36) | PDE2AHTR1APTPN1CDC25BPTPN2 | |
| SCHEMBL19412708 | 0.82 | PTPN1 (0.34) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL17106669 | 0.82 | PTPN1 (0.34) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL12243227 | 0.80 | PDE2A (0.37) | PDE2AHTR1APTPN1CDC25BHSPA5 | |
| SCHEMBL20434901 | 0.79 | PDE2A (0.37) | PDE2AHTR1APTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | PDE2A 255/4885HTR1A 1140/4885PTPN1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.